Developments in biomedical technology will increase the importance of mRNA in treating brain tumors, as well as other malignancies

RNA was previously believed to be a genetic substance in animals rather than DNA because it was more active in cells than DNA, and conveyed codons often into and out of the nuclear pore, which helped organism development and reproduction and was necessary for biological life. Until later, it was discovered that certain viruses' genetic material is RNA rather than DNA, and American scientists Baltimore and Termin discovered reverse transcriptase in viruses that could reverse transcribe RNA into DNA; hence, RNA was shown to have a strong gene transcription function. Three high-profile areas of modern cancer research focus on three distinct areas: The abundance of non-coding RNAs such as lncRNAs, miRNAs, and circRNAs are intensely studied as they do not change the transcription of mRNAs;For diagnosis and prognosis, the expression level of mRNA can serve as a crucial biomarker, as it is carried by the body rather than being an invasive molecule. In addition, because primary brain malignancies are typically caused by genetic abnormalities, mRNA may be used to discover cures for these malignancies, which might potentially be utilized in gene therapy. In vitro transcription messenger RNA (IVT mRNA)-related technologies have been introduced in recent years, and using IVT mRNA, it is possible to stimulate de novo protein synthesis without altering the physiological status of the cells to which they are applied. Increasingly, developments in biomedical technology will increase the importance of mRNA in treating brain tumors, as well as other malignancies, and study of related research and function will also expand.

Biomedical Technology Innovation Education and Its Effect on Graduate Student Careers Over 17 Years

In the 1990s, interest in biomedical technologies blossomed among students across disciplines. In parallel, there was a push in academia to develop courses enabling interdisciplinary problem solving and more holistic, practice-oriented education. In response, Stanford Biodesign created a graduate course in biomedical technology innovation. Seventeen years later, we sought to gauge the impact of this course on student commitment to careers in biomedical technology, whether students took on leadership and innovation roles, and if they found the holistic innovation process we teach to be useful in their careers. We disseminated a web-based survey to collect self-reported data from students completing the course between 2003 and 2019. 186 students responded (24.8%). 62% (n = 115/186) reported a strong commitment to careers in biomedical technology before the course while 84% (n = 156/186) felt that way after. The improvement in mean scores from pre-course (3.8) to post-course (4.3) was statistically significant (p < 0.0001). Additionally, 78% (n = 145/186) currently work in healthcare, with 72% of those (n = 115/145) in biomedical technology. 82% (n = 146/179) were in innovation roles and 58% (n = 102/177) were in leadership positions. Nearly 94% (n = 161/172) found the course influential and the process to be useful in their careers. The data suggest that the course is perceived as valuable and is effective at creating and/or sustaining student interest in biomedical technology innovation. The results point to multiple improvement opportunities that are important for keeping the course relevant.

The problem of dignity in the context of genetic editing technology

The вiscussion about the legal regulation of biomedical technologies flared up with renewed vigor after the data on the He Jiankui experiment, the essence of which was artificial editing of the genome of human embryos. This work investigates the problem of applying the principle of personality achievement in the discourse of legal regulation of genetic editing technology. Given the fact that there are a number of rules governing certain cases of genome editing, this work focuses on the study of cases prohibited by current international law. Most of these cases of application of this biomedical technology are associated with humiliation of human dignity, for this reason, this article examines exclusively the connection of this universal value with genetic editing. The article highlights the main problems of the concept of achievement, the use of genetic editing technology, as well as its legal regulation. In addition, the basis of arguments is considered separately, on the basis of which opponents of the application of the technology under consideration apply to the concept of achievement and its humiliation.

Biomedical packages

Clinical trials are a fundamental stage in a drug’s biography for they provide the standard by which a molecule’s therapeutic status is determined. Through this process of experimentation, a pharmaceutical substance acquires a new competence – that of treating or preventing disease. This article examines experimentation in drug production, and shows how this complex apparatus not only transforms the status of the molecule but also produces new understandings of and expectations for how people should act. Drawing upon observation of a trial of prophylactic prevention of mother-to-child transmission of HIV, in Ouagadougou, Burkina Faso, I show that the production of this biomedical technology – the therapeutic drug – is coupled with the production of its users. In so doing, I challenge the conception of drugs as bounded objects and instead offer the concept of ‘biomedical package’, which highlights the social relations that characterise it.

Tecnologias em saúde aplicadas na reabilitação de mulheres com câncer de mama: scoping review

Objetivo: Identificar as tecnologias em saúde na reabilitação física de mulheres que desenvolveram alterações no membro superior homolateral após a cirurgia para o câncer de mama. Método: Trata-se de uma Scoping literature review. Realizou-se a busca nas bases de dados LILACS, PubMed e Web of Science e o mecanismo de busca Google Scholar. Os descritores utilizados foram: Breast neoplasms, Biomedical technology e Rehabilitation. Resultados: Foram selecionados 33 estudos. Entre as tecnologias leve-duras, a mais utilizada foram os programas de exercícios físicos, tanto para a limitação da amplitude de movimentos do membro superior quanto para o linfedema, sendo estas as mais estudadas. Já as tecnologias duras mais avaliadas foram acupuntura, terapia de laser de baixo nível e plataformas de exercício on line, sendo empregadas, principalmente, para complicações como dor e linfedema. Destaque para a inter-relação entre as diferentes tecnologias, e como estas compõem a assistência prestadas às mulheres com câncer de mama durante a reabilitação física. Conclusão: A maioria dos estudos utilizaram as tecnologias leve-duras, com destaque para os programas de exercícios, e a associação de diferentes tecnologias, de intensidade variadas, empregadas com bons resultados físicos. Além de atuarem no estímulo ao autocuidado e na orientação das mulheres quanto a autogestão das complicações, promovendo a autonomia, confiança e retomada de seus papéis sociais.

China and Russia tactics will undercut their vaccines

Significance For Russia, it would be a chance for international acclaim and to stoke national pride. For China, success would offset its shortcomings in responding to the emergence of COVID-19 and would demonstrate superior biomedical technology to the world and its own citizens. These two governments' efforts can influence the speed at which the pandemic is brought under control. Impacts Multiple successful vaccines would help overcome production and logistical challenges to meet global demand. The value of vaccine development companies is likely to be volatile, as phase III trials and results are reported over the next few months. Western states will be reluctant to take Chinese or Russian vaccines. Some regional vaccine blocs, mirroring global powers' spheres of influence, could emerge. Moscow may use disinformation to sow distrust of vaccines in Western countries, slowing innoculations and eroding trust in government.